HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

scientific article

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1172/JCI75894
P932PMC publication ID4347219
P698PubMed publication ID25271627

P50authorBarton HaynesQ4865631
Julie McElrathQ22006776
David C. MontefioriQ63302725
Georgia D. TomarasQ63663866
Giuseppe PantaleoQ88061163
Hua-Xin LiaoQ88608388
Barney S. GrahamQ89108863
Shelly T KarunaQ114519526
Yunda HuangQ40049651
P2093author name stringPeter B Gilbert
Xiaoying Shen
Pierre-Alexandre Bart
Song Ding
Nicole Frahm
John Hural
Mary A Allen
Julien Gaillard
Samuel Chappuis
Nidhi Kochar
P2860cites workPolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsQ24635002
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Q28741673
Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectorsQ40162047
Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccinesQ40578949
Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost.Q42980826
Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccinationQ43125298
DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine modelQ44394460
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patientsQ44766920
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluationQ45413707
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env geneQ45785380
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneQ46576663
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trialsQ53475786
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc ConsortiumQ54454033
Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy AdultsQ58436528
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialQ28972526
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandQ29547531
Immune-correlates analysis of an HIV-1 vaccine efficacy trialQ29617377
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesQ29619015
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineQ30578618
Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine DevelopmentQ33586290
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodiesQ33614365
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.Q33693391
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)Q33737476
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMCQ34357068
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialQ34374835
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infectionQ34402934
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimensQ34438489
Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injectionQ34531535
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsQ34593969
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesQ34772727
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaQ34848486
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay systemQ35060140
HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectableQ35234257
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccineQ35640645
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysQ35729899
Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trialsQ35865556
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsQ36083337
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesQ36446900
Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).Q36495587
Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectorsQ36559772
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.Q36668517
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumorsQ36690209
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.Q36895518
Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infectionQ37187509
Heterologous prime-boost vaccination.Q37509586
The role of antibodies in HIV vaccinesQ37700725
Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cellsQ39017459
Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assaysQ39988991
P433issue11
P407language of work or nameEnglishQ1860
P304page(s)4843-4856
P577publication date2014-10-01
P1433published inJournal of Clinical InvestigationQ3186904
P1476titleHIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
P478volume124

Reverse relations

cites work (P2860)
Q35593139A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults
Q36003208A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine
Q40844843A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract
Q27314516COMPASS identifies T-cell subsets correlated with clinical outcomes
Q35808262Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses
Q40235609Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.
Q47105096Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine.
Q40339467HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci
Q35914311Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates
Q38748193New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.
Q38675720Prime-boost vaccine strategy against viral infections: Mechanisms and benefits.
Q92288781Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector
Q35798892Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.
Q26801501Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data
Q36192765Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
Q26770839Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective
Q26995905The evolution of poxvirus vaccines

Search more.